Advertisement

Uterine Cancer pp 313-320 | Cite as

Surgery for Advanced Endometrial Cancer

  • Shalini Rajaram
  • Monisha Gupta

Abstract

In approximately 10–15 % of all new cases of endometrial cancer, disease is found outside the uterus. These cases account for more than 50 % of all uterine cancer-related deaths, with survival rates as low as 5–15 % [2, 3]. Due to rarity of such cases, no randomized controlled trials currently provide insight on the best treatment options. This chapter will present current best management options.

Keywords

Endometrial Cancer Cytoreductive Surgery Gynecology Oncology Group Adjuvant Chemoradiation Optimal Cytoreduction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Tangjitgamol S, Anderson BO, et al. Management of endometrial cancer in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009;10:1119–27.CrossRefPubMedGoogle Scholar
  2. 2.
    Colombo N, Preti E, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Supplement 6):vi33–8.PubMedGoogle Scholar
  3. 3.
    Burke WM, Orr J. Endometrial cancer: a review and current management strategies: part I. Gynecol Oncol. 2014;134:385–92.CrossRefPubMedGoogle Scholar
  4. 4.
    del Carmen MG, Birrer M. Uterine papillary serous cancer: a review of the literature. Gynecol Oncol. 2012;127:651–61.CrossRefPubMedGoogle Scholar
  5. 5.
    Olawaiye AB, Boruta D. Management of women with clear cell endometrial cancer. A Society of Gynecologic Oncology (SGO) review. Gynecol Oncol. 2009;113:277–83.CrossRefPubMedGoogle Scholar
  6. 6.
    Tanner EJ, Leitao Jr MM. The role of cytoreductive surgery for newly diagnosed advanced-stage uterine carcinosarcoma. Gynecol Oncol. 2011;123:548–52.CrossRefPubMedGoogle Scholar
  7. 7.
    Havrilesky LJ, Secord AA, Bae-Jump V, et al. Outcomes in surgical stage I uterine papillary serous carcinoma. Gynecol Oncol. 2007;105:677.CrossRefPubMedGoogle Scholar
  8. 8.
    Fader AN, Starks D, Gehrig PA, et al. An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). Gynecol Oncol. 2009;115:244.CrossRefPubMedGoogle Scholar
  9. 9.
    Kelly MG, O’malley DM, Hui P, et al. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol. 2005;98:353.CrossRefPubMedGoogle Scholar
  10. 10.
    Varughese J, Hui P, Lu L, et al. Clear cell cancer of the uterine corpus: the association of clinicopathologic parameters and treatment on disease progression. J Oncol. 2011;2011:628084.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Creasman WT, et al. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group study. Cancer. 1987;60(8 Suppl):2035–41.CrossRefPubMedGoogle Scholar
  12. 12.
    Manfredi R, Mirk P, Maresca G, et al. Local-regional staging of endometrial carcinoma: role of MR imaging in surgical planning. Radiology. 2004;231:372–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Sala E, Wakely S, Senior E, et al. MRI of malignant neoplasms of the uterine corpus and cervix. Am J Roentgenol. 2007;188:1577–87.CrossRefGoogle Scholar
  14. 14.
    Kitajima K, et al. Accuracy of integrated FDG-PET/contrast-enhanced CT in detecting pelvic and paraaortic lymph node metastasis in patients with uterine cancer. Eur Radiol. 2009;19(6):1529–36.CrossRefPubMedGoogle Scholar
  15. 15.
    Shih KK, et al. Surgical cytoreduction in stage IV endometrioid endometrial carcinoma. Gynecol Oncol. 2011;122(3):608–11.CrossRefPubMedGoogle Scholar
  16. 16.
    Lambrou NC, et al. Optimal surgical cytoreduction in patients with stage III and stage IV endometrial carcinoma: a study of morbidity and survival. Gynecol Oncol. 2004;93(3):653–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Goff BA, et al. Surgical stage IV endometrial carcinoma: a study of 47 cases. Gynecol Oncol. 1994;52(2):237–40.CrossRefPubMedGoogle Scholar
  18. 18.
    Bristow RE, Zerbe MJ, et al. Stage IVB endometrial cancer: the role of cytoreductive surgery and determinants of survival. Gynecol Oncol. 2000;78:85–91.CrossRefPubMedGoogle Scholar
  19. 19.
    Walker JL, et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 study–70. J Clin Oncol. 2012;30(7):6950.CrossRefGoogle Scholar
  20. 20.
    Zivanovic O, et al. The rate of port-site metastases after 2251 laparoscopic procedures in women with underlying malignant disease. Gynecol Oncol. 2008;111(3):431–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Palomba S, Falbo A, Russo T, La Sala GB. Port-site metastasis after laparoscopic surgical staging of endometrial cancer: a systematic review of the published and unpublished data. J Minim Invasive Gynecol. 2012;19(4):531–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Bristow RE, Duska LR, Montz FJ. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma. Gynecol Oncol. 2001;81:92–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Thomas MB, Mariani A, Cliby WA, Keeney GL, Podratz KC, Dowdy SC. Role of cytoreduction in stage III and IV uterine papillary serouscarcinoma. Gynecol Oncol. 2007;107:190–3.CrossRefPubMedGoogle Scholar
  24. 24.
    Vandenput I, Van Calster B, Capoen A, et al. Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? Br J Cancer. 2009;101:244–9.PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Vergote I, De Wever I, Tjalma W, Van Gramberen M, Decloedt J, van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol. 1998;71:431–6.CrossRefPubMedGoogle Scholar
  26. 26.
    McMeekin DS, Lashbrook D, Gold M, Scribner DR, Kamelle S, Tillmanns TD, et al. Nodal distribution and its significance in FIGO stage IIIC endometrial cancer. Gynecol Oncol. 2001;82:375–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Aalders JG, Thomas G. Endometrial cancer – revisiting the importance of pelvic and paraaortic lymph nodes. Gynecol Oncol. 2007;104:222–31.CrossRefPubMedGoogle Scholar
  28. 28.
    Randall ME, Filiaci VL, Muss H, et al. Randomised phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2006;24:36–44.CrossRefPubMedGoogle Scholar
  29. 29.
    Susumu N, Sagae S, Udagawa Y, et al. Randomised phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol. 2008;108:226–33.CrossRefPubMedGoogle Scholar
  30. 30.
    Hogberg T, Signorelli M, de Oliveira CF, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer – results form two randomised studies. Eur J Cancer. 2010;46:2422–31.PubMedCentralCrossRefPubMedGoogle Scholar
  31. 31.
    Humber CE, Tierney JF, Symonds RP, et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol. 2007;18:409–20.CrossRefPubMedGoogle Scholar
  32. 32.
    Rauh-Hain JA, Del Carmen MG. Treatment for advanced and recurrent endometrial carcinoma: combined modalities. Oncologist. 2010;15:852–61.PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    Memarzadeh S, Holschneider SH, Bristow RE, Jones NL, Fu YS, Karlan BY, Berek JS, Farias-Eisner R. FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival. Int J Gynecol Cancer. 2002;12:454–58.Google Scholar
  34. 34.
    Lee TD, Yamada SD, Rutgers JL, DiSaia PJ. Case report: complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with taxol and carboplatin. Gynecol Oncol. 1999;73:461–3.Google Scholar
  35. 35.
    Prince F, Amin R, Sumkin J. Case report: complete clinical responses to neo-adjuvant chemotherapy for uterine serous carcinoma. Gynecol Oncol. 1999;73:140–4.Google Scholar

Copyright information

© Springer India 2015

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyUniversity College of Medical Sciences and Guru Teg Bahadur HospitalDelhiIndia
  2. 2.Department of Gynecologic OncologyGujarat Cancer Research Institute (GCRI)AhmedabadIndia

Personalised recommendations